WuXi PharmaTech has signed a new three-year CRO deal with Pfizer to collaborate on in vitro ADME (Absorption, Distribution, Metabolism and Excretion) services. Although WuXi has already been providing the services to Pfizer, WuXi said the new agreement “strengthens an already productive relationship.” WuXi also provides Pfizer with synthetic chemistry, parallel medicinal chemistry (PMC), and bioanalytical services. More details...

Stock Symbols: (NYSE: WX) (NYSE: PFE)